These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 8458475)

  • 1. The safety of physiological estrogen plus progestin replacement therapy and with oral contraceptive therapy in women with pathological hyperprolactinemia.
    Corenblum B; Donovan L
    Fertil Steril; 1993 Mar; 59(3):671-3. PubMed ID: 8458475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two-year treatment with oral contraceptives in hyperprolactinemic patients.
    Testa G; Vegetti W; Motta T; Alagna F; Bianchedi D; Carlucci C; Bianchi M; Parazzini F; Crosignani PG
    Contraception; 1998 Aug; 58(2):69-73. PubMed ID: 9773260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of contraceptive steroids on hypothalamic-pituitary function.
    Mishell DR; Kletzky OA; Brenner PF; Roy S; Nicoloff J
    Am J Obstet Gynecol; 1977 May; 128(1):60-74. PubMed ID: 403765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exogenous progestins and breast cancer.
    Stanford JL; Thomas DB
    Epidemiol Rev; 1993; 15(1):98-107. PubMed ID: 8405216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pituitary function is altered during the same cycle in women with polycystic ovary syndrome treated with continuous or cyclic oral contraceptives or a gonadotropin-releasing hormone agonist.
    Ruchhoft EA; Elkind-Hirsch KE; Malinak R
    Fertil Steril; 1996 Jul; 66(1):54-60. PubMed ID: 8752611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses.
    Raudaskoski TH; Lahti EI; Kauppila AJ; Apaja-Sarkkinen MA; Laatikainen TJ
    Am J Obstet Gynecol; 1995 Jan; 172(1 Pt 1):114-9. PubMed ID: 7847516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone mineral changes in young women with hypothalamic amenorrhea treated with oral contraceptives, medroxyprogesterone, or placebo over 12 months.
    Hergenroeder AC; Smith EO; Shypailo R; Jones LA; Klish WJ; Ellis K
    Am J Obstet Gynecol; 1997 May; 176(5):1017-25. PubMed ID: 9166162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential regimen of the antiprogesterone RU486 and synthetic progestin for contraception.
    Kekkonen R; Lähteenmäki P; Luukkainen T; Tuominen J
    Fertil Steril; 1993 Oct; 60(4):610-5. PubMed ID: 8405512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The significance of galactorrhea in patients with normal menses, oligomenorrhea, and secondary amenorrhea.
    Davajan V; Kletzky O; March CM; Roy S; Mishell DR
    Am J Obstet Gynecol; 1978 Apr; 130(8):894-904. PubMed ID: 565142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hormonal replacement therapy in menopausal women with a history of hyperprolactinemia.
    Touraine P; Deneux C; Plu-Bureau G; Mauvais-Jarvis P; Kuttenn F
    J Endocrinol Invest; 1998 Dec; 21(11):732-6. PubMed ID: 9972671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contraceptive steroid effects on nonreproductive organ systems.
    Corson SL
    J Reprod Med; 1986 Sep; 31(9 Suppl):865-78. PubMed ID: 3772906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Control of fertility with oral medication.
    Diddle AW; Watts GF; Gardner WH; Williamson PJ
    West J Surg Obstet Gynecol; 1964; 72():222-9. PubMed ID: 12305556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the effects of contraceptive steroid formulations containing two doses of estrogen on pituitary function.
    Scott JZ; Kletzky OA; Brenner PF; Mishell DR
    Fertil Steril; 1978 Aug; 30(2):141-5. PubMed ID: 98356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contraceptive choices for women with endocrine complications.
    Loriaux DL; Wild RA
    Am J Obstet Gynecol; 1993 Jun; 168(6 Pt 2):2021-6. PubMed ID: 8512047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Partial hypopituitarism and hyperprolactinemia: successful induction of ovulation with bromocriptine and human menopausal gonadotropins.
    Dawood MY; Jarrett JC; Choe JK
    Fertil Steril; 1982 Oct; 38(4):415-8. PubMed ID: 6811337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pill-a-month as an oral contraceptive.
    Hefnawi F; Hassanein M; Younis N
    Egypt Popul Fam Plann Rev; 1972 Jun; 5(1):1-17. PubMed ID: 12256024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pituitary prolactinoma and estrogen contraceptives.
    Vaisrub S
    JAMA; 1979 Jul; 242(2):177-8. PubMed ID: 12309457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparative study of the effects of an estradiol-releasing vaginal ring combined with an oral gestagen versus transdermal estrogen combined with a levonorgestrel-releasing IUD: clinical findings and endometrial response.
    Kalogirou D; Antoniou G; Karakitsos P; Kalogirou O; Antoniou D; Giannikos L
    Int J Fertil Menopausal Stud; 1996; 41(6):522-7. PubMed ID: 9010746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The trimonthly combination oral contraceptive regimen: is it cost effective?
    Schwartz JL; Creinin MD; Pymar HC
    Contraception; 1999 Nov; 60(5):263-7. PubMed ID: 10717777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A practical guide to the diagnosis and management of amenorrhoea.
    Crosignani PG; Vegetti W
    Drugs; 1996 Nov; 52(5):671-81. PubMed ID: 9118817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.